Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Lisdexamfetamine Dimesylate (LDX) 30 mg
Total, all-cause mortality	LDX 50 mg
Total, all-cause mortality	LDX 70 mg
Total, all-cause mortality	Placebo
Total, other adverse events	Lisdexamfetamine Dimesylate (LDX) 30 mg	51	78
Total, other adverse events	LDX 50 mg	53	77
Total, other adverse events	LDX 70 mg	56	78
Total, other adverse events	Placebo	38	77
Total, serious adverse events	Lisdexamfetamine Dimesylate (LDX) 30 mg	0	78
Total, serious adverse events	LDX 50 mg	0	77
Total, serious adverse events	LDX 70 mg	0	78
Total, serious adverse events	Placebo	0	77

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00735371/event-totals